SEARCH

SEARCH BY CITATION

References

  • Advani, R.H., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B., Kolibaba, K.S., Furman, R.R., Rodriguez, S., Chang, B.Y., Sukbuntherng, J., Izumi, R., Hamdy, A., Hedrick, E. & Fowler, N.H. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 31, 8894.
  • Boyd, R.S., Jukes-Jones, R., Walewska, R., Brown, D., Dyer, M.J. & Cain, K. (2009) Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Molecular & Cellular Proteomics, 8, 15011515.
  • Buggy, J.J. & Elias, L. (2012) Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. International Reviews of Immunology, 31, 119132.
  • Chang, B.Y., Furman, R.R., Zapatka, M., Barrientos, J.C., Li, D., Steggerda, S., Eckert, K., Francesco, M., Woyach, J.A. & Johnson, A.J. (2013a) Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology, 31 (Suppl; abtract 7014).
  • Chang, B.Y., Francesco, M., De Rooij, M.F., Magadala, P., Steggerda, S.M., Huang, M.M., Kuil, A., Herman, S.E., Chang, S., Pals, S.T., Wilson, W., Wiestner, A., Spaargaren, M., Buggy, J.J. & Elias, L. (2013b) Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood, 122, 24122424.
  • Cheng, S., Coffey, G., Zhang, X.H., Shaknovich, R., Song, Z., Lu, P., Pandey, A., Melnick, A.M., Sinha, U. & Wang, Y.L. (2011) SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood, 118, 63426352.
  • Cheng, S., Ma, J., Guo, A., Lu, P., Coleman, M., Liu, M., Buggy, J.J., Furman, R.R. & Wang, Y.L. (2014) BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia, 28, 649657.
  • Chiorazzi, N., Rai, K.R. & Ferrarini, M. (2005) Chronic lymphocytic leukemia. New England Journal of Medicine, 352, 804815.
  • Cinar, M., Hamedani, F., Mo, Z., Cinar, B., Amin, H.M. & Alkan, S. (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leukemia Research, 37, 12711277.
  • Dal Porto, J.M., Gauld, S.B., Merrell, K.T., Mills, D., Pugh-Bernard, A.E. & Cambier, J. (2004) B cell antigen receptor signaling 101. Molecular Immunology, 41, 599613.
  • Dasmahapatra, G., Patel, H., Dent, P., Fisher, R.I., Friedberg, J. & Grant, S. (2013) The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. British Journal of Haematology, 161, 4356.
  • Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 8892.
  • Deng, C., Lee, S. & O'Connor, O.A. (2012) New strategies in the treatment of mantle cell lymphoma. Clinical Cancer Research, 18, 34993508.
  • Fluckiger, A.C., Li, Z., Kato, R.M., Wahl, M.I., Ochs, H.D., Longnecker, R., Kinet, J.P., Witte, O.N., Scharenberg, A.M. & Rawlings, D.J. (1998) Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO Journal, 17, 19731985.
  • Furman, R.R., Cheng, S., Lu, P., Setty, M., Perez, A., Guo, A., Racchumi, J., Ma, J., Coleman, M., Venkataraman, J., Xu, G.Z., Chen, W., Wu, H., Betty, Y.C., Leslie, C. & Wang, Y.L. (2013) A Novel BTK Mutation reactivates BCR signaling and confers acquired resistance of CLL to ibrutinib. Blood (ASH Annual Meeting Abstract), 122, 4914.
  • Furman, R.R., Cheng, S., Lu, P., Setty, M., Perez, S.A., Guo, A., Racchumi, J., Xu, G.Z., Wu, H., Ma, J., Susanne, M., Coleman, M., Leslie, C. & Wang, Y.L. (2014) A novel mutation in Bruton tyrosine kinase confers acquired resistance to ibrutinib in chronic lymphocytic leukemia. New England Journal of Medicine, doi:10.1056/NEJMc1402716.
  • de Gorter, D.J., Beuling, E.A., Kersseboom, R., Middendorp, S., van Gils, J.M., Hendriks, R.W., Pals, S.T. & Spaargaren, M. (2007) Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity, 26, 93104.
  • Hadzidimitriou, A., Agathangelidis, A., Darzentas, N., Murray, F., Delfau-Larue, M.H., Pedersen, L.B., Lopez, A.N., Dagklis, A., Rombout, P., Beldjord, K., Kolstad, A., Dreyling, M.H., Anagnostopoulos, A., Tsaftaris, A., Mavragani-Tsipidou, P., Rosenwald, A., Ponzoni, M., Groenen, P., Ghia, P., Sander, B., Papadaki, T., Campo, E., Geisler, C., Rosenquist, R., Davi, F., Pott, C. & Stamatopoulos, K. (2011) Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood, 118, 30883095.
  • Harwood, N.E. & Batista, F.D. (2010) Early events in B cell activation. Annual Reviews of Immunology, 28, 185210.
  • Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D.H., Miller, R.A. & Buggy, J.J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 1307513080.
  • Humphries, L.A., Dangelmaier, C., Sommer, K., Kipp, K., Kato, R.M., Griffith, N., Bakman, I., Turk, C.W., Daniel, J.L. & Rawlings, D.J. (2004) Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. Journal of Biological Chemistry, 279, 3765137661.
  • Irish, J.M., Czerwinski, D.K., Nolan, G.P. & Levy, R. (2006) Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood, 108, 31353142.
  • Jares, P., Colomer, D. & Campo, E. (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nature Reviews Cancer, 7, 750762.
  • Jiang, A., Craxton, A., Kurosaki, T. & Clark, E.A. (1998) Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. Journal of Experimental Medicine, 188, 12971306.
  • Kuppers, R. (2005) Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews Cancer, 5, 251262.
  • Kurosaki, T., Shinohara, H. & Baba, Y. (2010) B cell signaling and fate decision. Annual Review of Immunology, 28, 2155.
  • Lu, P., Yang, C., Harrington, G.W., Wang, Y.L. & Cesarman, E. (2009) Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma. Leukemia, 23, 807810.
  • Macias-Perez, I.M. & Flinn, I.W. (2012) B-cell receptor pathobiology and targeting in NHL. Current Oncology Reports, 14, 411418.
  • Pan, Z., Scheerens, H., Li, S.J., Schultz, B.E., Sprengeler, P.A., Burrill, L.C., Mendonca, R.V., Sweeney, M.D., Scott, K.C., Grothaus, P.G., Jeffery, D.A., Spoerke, J.M., Honigberg, L.A., Young, P.R., Dalrymple, S.A. & Palmer, J.T. (2007) Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem, 2, 5861.
  • Parekh, S., Weniger, M.A. & Wiestner, A. (2011) New molecular targets in mantle cell lymphoma. Seminars in Cancer Biology, 21, 335346.
  • Perez-Galan, P., Dreyling, M. & Wiestner, A. (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood, 117, 2638.
  • Pighi, C., Gu, T.L., Dalai, I., Barbi, S., Parolini, C., Bertolaso, A., Pedron, S., Parisi, A., Ren, J., Cecconi, D., Chilosi, M., Menestrina, F. & Zamo, A. (2011) Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cellular Oncology (Dordrecht), 34, 141153.
  • Rinaldi, A., Kwee, I., Taborelli, M., Largo, C., Uccella, S., Martin, V., Poretti, G., Gaidano, G., Calabrese, G., Martinelli, G., Baldini, L., Pruneri, G., Capella, C., Zucca, E., Cotter, F.E., Cigudosa, J.C., Catapano, C.V., Tibiletti, M.G. & Bertoni, F. (2006) Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. British Journal of Haematology, 132, 303316.
  • Song, Z., Lu, P., Furman, R.R., Leonard, J.P., Martin, P., Tyrell, L., Lee, F.Y., Knowles, D.M., Coleman, M. & Wang, Y.L. (2010) Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clinical Cancer Research, 16, 587599.
  • Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., Jurczak, W., Advani, R.H., Romaguera, J.E., Williams, M.E., Barrientos, J.C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W.W., Johnson, P., Spurgeon, S.E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J.J., Chang, B.Y., Beaupre, D.M., Kunkel, L.A. & Blum, K.A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 369, 507516.
  • Wilson, W.H., Gerecitano, J.F., Goy, A., de Vos, S., Kenkre, V.P., Barr, P.M., Blum, K.A., Shustov, A.R., Advani, R.H., Lih, J., Williams, M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Kunkel, L.A., McGreivy, J., Balasubramanian, S., Cheng, M., Moussa, D., Buggy, J.J. & Staudt, L.M. (2012) The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood (ASH Annual Meeting Abstracts), 120, 686.
  • Yang, C., Lu, P., Lee, F.Y., Chadburn, A., Barrientos, J.C., Leonard, J.P., Ye, F., Zhang, D., Knowles, D.M. & Wang, Y.L. (2008) Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia, 22, 17551766.
  • Yang, Y., Shaffer, A.L. 3rd, Emre, N.C., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., Young, R.M., Zhao, H., Yang, Y., Xu, W., Buggy, J.J., Balasubramanian, S., Mathews, L.A., Shinn, P., Guha, R., Ferrer, M., Thomas, C., Waldmann, T.A. & Staudt, L.M. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell, 21, 723737.
  • Young, R.M. & Staudt, L.M. (2013) Targeting pathological B cell receptor signalling in lymphoid malignancies. Nature Reviews. Drug Discovery, 12, 229243.